title: Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen?
abstract: The optimal chemoradiation regimen for patients with locally advanced non-small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a "one size fits all" approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation.
authors.affiliation: Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. videtig@ccf.org.
authors.forename: Gregory M M
authors.initials: GM
authors.lastname: Videtic
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D060830:Consolidation Chemotherapy / Q000379:methods; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome